Provider: View Press Release
Type: Link
Title: Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate | GSK
Description: Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
Provider: View Press Release
Type: Link
Title: Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant | GSK
Description: New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv
Provider: View Press Release
Type: Link
Title: GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children | GSK
Description: Gavi to provide funding for procurement and introduction of malaria vaccines into child immunisation programmes in Gavi eligible countries.
Provider: View Press Release
Type: Link
Title: MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab) | GSK
Description: Conditional marketing authorisation has been granted for Great Britain and is based on Phase III data
Provider: View Press Release
Type: Link
Title: GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease | GSK
Description: The institute aims to deepen understanding of complex diseases such as Alzheimer’s and Parkinson’s, and increase drug discovery.
Provider: View Press Release
Type: Link
Title: Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant | GSK
Description: Data to be confirmed by further in vitro pseudo-virus testing